FDA warns of breathing risks with popular nerve drugs
WASHINGTON (AP) — U.S. health regulators are warning that popular nervous system medications can cause dangerous breathing problems when combined with opioids and certain other drugs. The…
Related Articles
‘A bloodbath’: Trump administration moves to terminate scores of federal grants at Harvard – The Boston Globe
Harvard researchers who rely on federal grants to study cancer, infectious diseases and a range of other topics began receiving termination notices en masse on…
How Chronic Disease Became the Biggest Scourge in American Health
Americans live shorter and less healthy lives than people in other high-income countries.
France’s Sanofi plans to invest at least $20 billion in United States
Sanofi said on Wednesday it plans to invest at least $20 billion to boost manufacturing and research in the United States through 2030, becoming the…
Scientific societies call for a moratorium on using CRISPR to create genetically modified children
Leading trade organizations representing the makers of cell and gene therapies are calling for a 10-year moratorium on germline gene editing
Trump Targets Drug Prices with Executive Order
President Donald Trump has announced plans to sign an executive order on Monday, May 12, 2025, aiming to significantly lower prescription drug prices in the…
Gluten-free kisses? Study suggests people with celiac disease can smooch someone who ate gluten
The researchers wanted to learn whether a person with celiac disease could kiss a person who had just eaten gluten without triggering any symptoms.
Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI): a post-hoc analysis of a randomised, open-label, parallel-group, phase 3 trial
In the SURPASS-3 MRI substudy, in the context of significant improvements in bodyweight and fat distribution, tirzepatide treatment was associated with potentially favourable changes in…
Supreme Court sides with HHS on formula used to pay hospitals for treating low-income patients
In a 7-2 decision, the Supreme Court agreed with HHS’s narrow interpretation of how to pay hospitals for treating low-income patients.
Semaglutide and Tirzepatide Prescribing for Obesity
This study uses data from the US nationwide electronic health record–based Epic Cosmos Dataset to examine prescriptions for semaglutide and tirzepatide, focusing on differences across…
The end of compounded GLP-1 copies leaves many patients in a ‘lose-lose’ position
With GLP-1 shortage officially over, patients who relied on compounded copies have only bad options to choose from